BrightSpring Announces Secondary Offering of Common Stock

Concurrent share repurchase also announced as part of the transaction

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

BrightSpring Health Services, Inc., a leading provider of home and community-based health services, has announced the pricing of a previously disclosed underwritten secondary offering of 20,000,000 shares of its common stock by certain stockholders, including an affiliate of Kohlberg Kravis Roberts & Co. L.P. and certain members of management. The company will not receive any proceeds from the offering.

Why it matters

This secondary offering allows some of BrightSpring's major investors to monetize a portion of their holdings, while the concurrent share repurchase by the company suggests it views its stock as undervalued at the offering price. The transaction highlights the ongoing consolidation and financial activity in the home healthcare industry.

The details

The shares are being offered at a public price of $41.15 per share. In addition, BrightSpring has authorized the concurrent purchase of 1,464,807 shares from the underwriter at the same price per share. Goldman Sachs & Co. LLC is acting as the sole book-running manager for the offering.

  • The offering is expected to close on March 4, 2026, subject to customary closing conditions.
  • The closing of the share repurchase is conditioned on, and expected to occur simultaneously with, the closing of the offering.

The players

BrightSpring Health Services, Inc.

A leading provider of home and community-based health services for complex populations.

Kohlberg Kravis Roberts & Co. L.P.

An affiliate of this private equity firm is among the selling stockholders in the secondary offering.

Goldman Sachs & Co. LLC

The sole book-running manager for the secondary offering.

Got photos? Submit your photos here. ›

The takeaway

This transaction highlights the ongoing consolidation and financial activity in the home healthcare industry as major investors look to monetize their holdings, while the company's concurrent share repurchase suggests it views its stock as undervalued at the offering price.